NEW YORK (GenomeWeb News) – Pathogenica said today that it will co-market with Illumina a new version of its HAI BioDetection kit on Illumina's MiSeq desktop sequencing system in the Asia Pacific region.
The new version of the kit, which uses targeted next-generation sequencing to detect bacterial strains involved in hospital acquired infections, will enable users to identify an expanded panel of bacteria and drug-resistant genes.
The kit is still under development and will be research-use only. Between 24 and 48 samples can be processed simultaneously per sequencing run.
Among the bacteria species that can be identified and sub-typed are Acinetobacter baumannii, Clostridium difficile, Escherichia coli, Klebsiella pneumonia, Pseudomonas aeruginosa, and Staphylococcus aureus.
"The introduction of an Illumina-compatible version of our kit emphasizes the platform-agnostic flexibility of our technology, and allows us to reach new users in the large number of clinical-facing facilities keen to use Illumina's sequencing technology," Pathogenica CEO Yemi Adesokan said in a statement.
Last year, Pathogenica inked a co-marketing agreement with Life Technologies to combine its kit with Life Tech's Ion Torrent PGM platform, and earlier this month, it announced agreements with two Dutch hospitals to evaluate the kit on the PGM for surveying and monitoring outbreaks and infectious bacteria.